Guideline Recommendations for Asthma Management

Maintenance Therapy with Inhaled Corticosteroids

Inhaled corticosteroids (ICS) are the cornerstone of long‑term control and should be prescribed as first‑line therapy for every patient with persistent asthma 1.
For mild persistent asthma, initiate low‑dose ICS (e.g., budesonide 200‑400 µg/day, fluticasone 100‑250 µg/day, or mometasone 200 µg/day) 1.
For moderate persistent asthma, start either low‑dose ICS + a long‑acting β‑agonist (LABA) or medium‑dose ICS as monotherapy 1.
For severe persistent asthma, the preferred regimen is high‑dose ICS combined with a LABA 1.

LABAs must never be prescribed without concurrent ICS because of FDA black‑box warnings; they are only acceptable as part of a fixed‑dose combination inhaler 1.

Approximately 80‑90 % of the maximal anti‑inflammatory benefit of ICS is achieved at low doses (≈ 200‑250 µg fluticasone‑equivalent per day); higher doses add little extra benefit but markedly increase systemic adverse‑effect risk 1.
Leukotriene receptor antagonists or 5‑lipoxygenase inhibitors (e.g., montelukast, zileuton) can be used when patients cannot or will not use an inhaled corticosteroid, although they are less effective than ICS 1.
Fixed‑dose combination inhalers that pair an ICS with a LABA (e.g., fluticasone/salmeterol, budesonide/formoterol) improve medication adherence and asthma control while allowing lower overall corticosteroid exposure 1.

Oral prednisone 40‑60 mg once daily (or divided twice daily) should be started immediately for any moderate‑to‑severe asthma exacerbation and continued until peak expiratory flow (PEF) reaches ≥ 70 % of predicted or the patient’s personal best 3.
The typical oral course lasts 5‑10 days for out‑patients; tapering is unnecessary when the total duration is < 10 days, especially if the patient is already on an inhaled corticosteroid 3.
In children, prescribe prednisone 1‑2 mg/kg/day (maximum 60 mg/day) divided twice daily for 3‑10 days, calculating the dose on ideal body weight in overweight children to avoid excess exposure 3.
Oral administration is preferred and equally effective as intravenous therapy when gastrointestinal absorption is intact; intravenous hydrocortisone 200 mg bolus followed by 200 mg every 6 hours is reserved for patients who are vomiting, severely ill, or unable to take oral medication 3.

Albuterol (short‑acting β‑agonist) is first‑line: 2.5‑5 mg via nebulizer or 4‑8 puffs from a metered‑dose inhaler with spacer every 20 minutes for three doses, then every 1‑4 hours PRN 3.
Ipratropium bromide 0.5 mg should be added to albuterol for all moderate‑to‑severe exacerbations; this combination reduces the risk of hospitalization 3.
Intravenous magnesium sulfate 2 g infused over 20 minutes is indicated for severe exacerbations with FEV₁ or PEF < 40 % predicted after initial therapy, or when life‑threatening features are present 4.
Supplemental oxygen must be titrated to maintain SpO₂ > 90 % (≥ 95 % in pregnant patients or those with cardiac disease) 4.

Objective measurement of airflow limitation (PEF or FEV₁) within 15‑30 minutes of presentation is essential; reliance on clinical impression alone frequently underestimates severity 4.
Features indicating a severe exacerbation include inability to speak in full sentences, respiratory rate > 25 breaths/min, heart rate > 110 beats/min, and PEF < 50 % of predicted or personal best 4.
Life‑threatening signs that warrant immediate ICU consideration are PEF < 33 % predicted, silent chest, cyanosis, feeble respiratory effort, altered mental status, PaCO₂ ≥ 42 mmHg, bradycardia, or hypotension 4.

Patients may be discharged when PEF is ≥ 70 % of predicted or personal best, symptoms are minimal or absent, oxygen saturation is stable on room air, and they remain stable for 30‑60 minutes after the last bronchodilator dose 4.
After discharge, continue oral prednisone for 5‑10 days and increase the inhaled corticosteroid dose compared with the pre‑admission regimen 4.

Sedatives are absolutely contraindicated in acute asthma and must never be administered 4.
Do not delay systemic corticosteroid therapy while trialing bronchodilators; anti‑inflammatory effects require 6‑12 hours to manifest 4.
Always obtain an objective PEF or FEV₁ measurement; failure to do so leads to under‑recognition of severity 4.
Avoid prescribing oral prednisone > 60 mg daily, as doses above this threshold provide no additional benefit but increase adverse‑effect risk 5.
Doubling the inhaled corticosteroid dose during an exacerbation in patients who are already adherent to their controller therapy is ineffective and should be avoided 6.